Cellebrite DI Ltd. $CLBT Shares Sold by Lord Abbett & CO. LLC

Key Points

• Lord Abbett & CO. LLC has reduced its stake in Cellebrite DI Ltd. by 28.7%, now holding 520,804 shares after selling 209,535 shares in the first quarter.
• Analysts are optimistic about Cellebrite DI's future, with 8 analysts rating the stock as a buy and a consensus target price of $21.00, despite recent adjustments in individual price targets from firms like Lake Street Capital and JPMorgan Chase & Co..
• Cellebrite's latest earnings report showed a quarterly EPS of $0.12, surpassing analyst expectations and marking an 18.4% revenue increase compared to the previous year.

Lord Abbett & CO. LLC lessened its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 28.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 520,804 shares of the company's stock after selling 209,535 shares during the quarter. Lord Abbett & CO. LLC owned approximately 0.22% of Cellebrite DI worth $10,119,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of CLBT. LPL Financial LLC lifted its holdings in Cellebrite DI by 39.0% in the 4th quarter. LPL Financial LLC now owns 54,402 shares of the company's stock worth $1,198,000 after purchasing an additional 15,267 shares during the last quarter. Alliancebernstein L.P. grew its stake in Cellebrite DI by 109.7% in the fourth quarter. Alliancebernstein L.P. now owns 28,633 shares of the company's stock valued at $631,000 after purchasing an additional 14,981 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Cellebrite DI by 2.9% during the 4th quarter. Geode Capital Management LLC now owns 246,262 shares of the company's stock worth $5,425,000 after acquiring an additional 6,994 shares during the period. Wells Fargo & Company MN raised its holdings in Cellebrite DI by 76.3% in the 4th quarter. Wells Fargo & Company MN now owns 54,726 shares of the company's stock valued at $1,206,000 after acquiring an additional 23,688 shares in the last quarter. Finally, Invesco Ltd. acquired a new position in Cellebrite DI in the 4th quarter valued at $32,700,000. 45.88% of the stock is currently owned by institutional investors.

Cellebrite DI Trading Up 0.9%

NASDAQ CLBT traded up $0.1430 on Thursday, hitting $15.6230. 288,666 shares of the company were exchanged, compared to its average volume of 1,665,430. The company has a market cap of $3.74 billion, a P/E ratio of -20.49, a P/E/G ratio of 3.13 and a beta of 1.27. The firm has a 50 day moving average of $14.95 and a two-hundred day moving average of $17.65. Cellebrite DI Ltd. has a 1-year low of $13.10 and a 1-year high of $26.30.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its quarterly earnings data on Thursday, August 14th. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.01. The business had revenue of $113.28 million for the quarter, compared to analyst estimates of $112.33 million. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.Cellebrite DI's revenue was up 18.4% compared to the same quarter last year. During the same period last year, the firm posted $0.10 earnings per share. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Research analysts anticipate that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently issued reports on CLBT. Lake Street Capital reduced their target price on Cellebrite DI from $24.00 to $22.00 and set a "buy" rating for the company in a report on Friday, August 15th. JPMorgan Chase & Co. decreased their price target on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a research note on Monday, May 12th. Wall Street Zen upgraded shares of Cellebrite DI from a "hold" rating to a "buy" rating in a research note on Saturday, August 16th. Finally, Needham & Company LLC reduced their target price on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday, August 14th. Five analysts have rated the stock with a Buy rating, According to MarketBeat, Cellebrite DI presently has a consensus rating of "Buy" and a consensus target price of $22.40.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.